Company Filing History:
2 out of 118 
1 out of 3,923 
1 out of 1,209 
Years Active: 2005-2006
Title: The Innovative Contributions of Sandra Leta Silberman
Introduction
Sandra Leta Silberman is a notable inventor based in Randolph, NJ (US). She has made significant contributions to the field of pharmaceuticals, particularly in the treatment of abnormal cell growth and gastrointestinal stromal tumors. With a total of 3 patents to her name, her work has the potential to impact many lives.
Latest Patents
Silberman's latest patents include a method for treating abnormal cell growth using a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride. This method involves orally administering a therapeutically effective amount of a crystalline polymorph to subjects suffering from abnormal cell growth that expresses the epidermal growth factor receptor (EGFR). Another significant patent focuses on the treatment of gastrointestinal stromal tumors, utilizing a compound known as 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide or a pharmaceutically acceptable salt thereof.
Career Highlights
Throughout her career, Sandra has worked with prominent companies such as Osi Pharmaceuticals, Inc. and Novartis AG. Her experience in these organizations has allowed her to develop and refine her innovative ideas, contributing to advancements in medical treatments.
Collaborations
Some of her notable coworkers include Timothy Norris and Jeffrey W. Raggon. Their collaboration has likely fostered an environment of creativity and innovation, leading to the development of impactful medical solutions.
Conclusion
Sandra Leta Silberman exemplifies the spirit of innovation in the pharmaceutical industry. Her patents and collaborations highlight her commitment to improving healthcare through scientific advancements. Her work continues to inspire future generations of inventors and researchers.